FDA Develops Guidelines to Handle Expected Influx of Gene and Cell Therapy Approvals

Noting that the U.S. Food and Drug Administration (FDA) expects more than 200 investigational new drug applications (INDs) by 2020 per year, many of them cell and gene therapies, the agency issued an outline of new procedures it plans to implement this year.